Asset profile
difamilast · Moizerto / Adquey
Small molecule
Evidence outlook
Approved: Atopic Dermatitis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
69 competitors in this universe: 2 direct rivals (same mechanism and indication), 7 same-class, 60 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Difamilast (Moizerto / Adquey): this drug | Approved | Small molecule | PDE4 | ||
| Crisaborole (Eucrisa) | Approved | Small molecule | PDE4 | ||
| Roflumilast (Zoryve) | Approved | Small molecule | PDE4 | ||
| Apremilast (Otezla) | Approved | Small molecule | PDE4 | ||
| Opicapone (Ongentys) | Approved | Small molecule | COMT, PDE4 | ||
| Hemay005 | Phase 3 | Small molecule | PDE4 | ||
| HPP737 | Phase 3 | Small molecule | PDE4 | ||
| ALTO-101 | Phase 2 | Small molecule | PDE4 | ||
| PALI-2108 | Phase 2 | Small molecule | PDE4 | ||
| PF-07038124 | Phase 2 | Small molecule | PDE4 | ||
| Abrocitinib (Cibinqo) | Approved | Small molecule | JAK1 | ||
| Baricitinib (Olumiant) | Approved | Small molecule | JAK, JAK1/2 | ||
| Dupilumab (Dupixent) | Approved | Monoclonal antibody | IL-4R-alpha | ||
| Lebrikizumab (Ebglyss) | Approved | Monoclonal antibody | IL-13 | ||
| Nemolizumab (Nemluvio) | Approved | Monoclonal antibody | IL-31 receptor A | ||
| Ruxolitinib | Approved | Small molecule | JAK1/2 |
…and 54 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.